In NUP214-ABL1-positive ALL-SIL cells, imatinib plus MRK-560 reduced cell accumulation more than either agent alone. Separate pretreatment assays showed an enhanced imatinib response and a synergistic interaction. The long-term combination effect was not reproduced in RPMI-8402 or LOUCY comparator cells. [2]
In cultured mouse mammary CD11b+ cells, imatinib mesylate reduced fibrocyte colony number and size over 10 days. This colony endpoint does not identify whether proliferation or survival was primarily affected, and it does not establish an exclusive PDGFRα mechanism. [3]
Imatinib binding to the inactive Abl kinase domain
Biochemical assay · Unphosphorylated murine c-Abl kinase domain (residues 229–515); crystallographic comparator PD173955 [1]
The intact inhibitor occupies the ATP-binding region and stabilizes an inactive activation-loop conformation.
Literature-Reported Treatment Conditions
- Method
- X-ray crystallography
- Vehicle
- DMSO used for inhibitor dissolution
- Reported limits
- Counterion not specified; crystallographic binding is not an IC50 or cellular efficacy assay.
Methods and source locations
Compound reported in the paper: Imatinib; Compound label in the paper: STI-571
Active-moiety structural mechanism; no salt-specific potency.
pp. 4237–4239; Table 1; Figs. 1a and 3A–B
Abl–STI-571 diffraction resolution: X-ray crystallography — p. 4237, Table 1; p. 4238, Overall Features of the Structures
Binding conformation: Refined structure, PDB 1IEP — pp. 4238–4239, Structure of Abl Kinase Domain Bound to STI-571; Fig. 3A–B
Long-term ALL-SIL proliferation with imatinib and MRK-560
Cell-based study · ALL-SIL T-ALL cells carrying NUP214-ABL1; RPMI-8402 and LOUCY comparator cell lines [2]
Combined treatment reduced ALL-SIL cell accumulation more than either single treatment. Comparator lines did not show the same combination response.
Literature-Reported Treatment Conditions
- Treatment concentration
- Imatinib 10 nM; MRK-560 100 nM
- Exposure duration
- 14 days
- Method
- Serial cell counts by flow cytometry; fresh medium and compounds every 2–3 days
- Vehicle
- DMSO
- Co-treatment
- MRK-560 100 nM; single-agent and DMSO groups included
- Reported limits
- Vehicle percentage not specified for this experiment.
Methods and source locations
Compound reported in the paper: Imatinib mesylate; Compound label in the paper: Imatinib
Reported research material in this experiment; no current-lot identity, purity or performance validation.
Fig. 2g and caption; Results, MRK-560 combination with kinase inhibitors; Methods, Proliferation assays
Absolute cell accumulation over time: Flow cytometric counts; biological triplicates; mean ± SD — Fig. 2g; accompanying Results paragraph
MRK-560 pretreatment enhances the imatinib response in ALL-SIL
Cell-based study · ALL-SIL T-ALL cells [2]
Seven-day MRK-560 pretreatment increased the response to subsequent imatinib. The authors classified the combination as synergistic using the Chou–Talalay method.
Literature-Reported Treatment Conditions
- Treatment concentration
- MRK-560 pretreatment 0.1 or 1 µM; imatinib 0, 2.5, 5 or 10 nM in Fig. 2h
- Exposure duration
- 7-day pretreatment followed by 48-hour assay
- Method
- ATPlite proliferation endpoint; CompuSyn combination-index analysis
- Vehicle
- DMSO; compound concentrations normalized to DMSO
- Co-treatment
- MRK-560 pretreatment followed by imatinib; DMSO pretreatment control
- Reported limits
- Individual numeric combination indices are not tabulated in the adopted evidence; no exact curve values extracted.
Methods and source locations
Compound reported in the paper: Imatinib mesylate; Compound label in the paper: Imatinib
Reported research material in this experiment; no current-lot identity, purity or performance validation.
Fig. 2h–i and caption; Methods, Proliferation assays and statistical analyses
Relative cell number and combination interaction: ATPlite; biological triplicates in Fig. 2h; Chou–Talalay combination index in Fig. 2i — Fig. 2h–i and accompanying Results
Imatinib reduces mammary fibrocyte colony formation
Cell-based study · Mouse mammary-gland CD11b+ cells isolated by magnetic beads and cultured for fibrocyte colony formation [3]
Imatinib reduced colony number and colony size with increasing concentration. The endpoint does not distinguish reduced proliferation from increased apoptosis or establish exclusive PDGFRα causality.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5, 10 or 20 µM
- Exposure duration
- 10 days; medium/treatment renewed on day 5
- Method
- Crystal-violet staining and ImageJ quantification of colony number and size
- Vehicle
- PBS control specified in Methods 4.6
- Reported limits
- Lot and purity not reported; specific cellular mechanism of colony loss not determined.
Methods and source locations
Compound reported in the paper: Imatinib mesylate; Compound label in the paper: Imatinib
Reported research material in this experiment; no current-lot identity, purity or performance validation.
Results 2.5; Fig. 5D–F; Methods 4.6 and 4.9
Fibrocyte colony number and size: n = 3 mice/treatment group as captioned; cultures grown in triplicate; colony number: one-way ANOVA/Tukey; colony size: Kruskal–Wallis/Dunn; error bars mean ± SEM by Methods 4.9 — Fig. 5D–F and caption; Results 2.5